# Traws Pharma, Inc.

Traws Pharma, Inc. is a public company listed on Nasdaq as TRAW, headquartered in Newtown, PA, United States.

## Company overview

- **Legal name:** Traws Pharma, Inc.
- **Former names in filing history:** Onconova Therapeutics, Inc. (2010-03-04 to 2024-04-01); ONCONOVA THERAPEUTICS INC (2003-01-08 to 2009-05-26)
- **Classification:** Public company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Newtown, PA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **Ticker:** Nasdaq: TRAW
- **SEC CIK:** 0001130598

## About

Traws Pharma, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001130598, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2026-04-15, it reported annual revenue of USD 2,790,000; net income of USD 9,170,000; total assets of USD 10,617,000 for the fiscal period ended 2025-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2025-12-31)

- **Revenue:** $2.8M (USD 2,790,000)
- **Net income:** $9.2M (USD 9,170,000)
- **Total assets:** $10.6M (USD 10,617,000)
- **Operating cash flow:** -$18.2M (USD -18,185,000)

### FY2024 (period ended 2024-12-31)

- **Revenue:** $226,000 (USD 226,000)
- **Net income:** -$166.5M (USD -166,523,000)
- **Total assets:** $25.0M (USD 24,962,000)
- **Operating cash flow:** -$29.8M (USD -29,792,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $226,000 (USD 226,000)
- **Net income:** -$18.9M (USD -18,948,000)
- **Total assets:** $22.7M (USD 22,683,000)
- **Cash and equivalents:** $20.6M (USD 20,559,000)
- **Operating cash flow:** -$17.9M (USD -17,932,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $226,000 (USD 226,000)
- **Net income:** -$19.0M (USD -18,964,000)
- **Total assets:** $39.4M (USD 39,372,000)
- **Cash and equivalents:** $38.5M (USD 38,522,000)
- **Operating cash flow:** -$16.3M (USD -16,294,000)

## Recent SEC filings

- Form 10-Q — filed 2026-08-14 — period 2026-06-30 — 10-Q
- Form 8-K — filed 2026-08-14 — period 2026-08-14 — FORM 8-K
- Form 8-K — filed 2026-07-31 — period 2026-07-29 — FORM 8-K
- Form 8-K — filed 2026-07-10 — period 2026-07-10 — FORM 8-K
- Form 8-K — filed 2026-07-09 — period 2026-07-08 — FORM 8-K
- Form 8-K — filed 2026-06-22 — period 2026-06-22 — FORM 8-K
- Form 8-K — filed 2026-06-12 — period 2026-06-12 — FORM 8-K
- Form DEF 14A — filed 2026-05-29 — period 2026-07-08 — DEF 14A
- Form 8-K — filed 2026-05-27 — period 2026-05-27 — FORM 8-K
- Form 8-K — filed 2026-05-26 — period 2026-05-22 — FORM 8-K
- Form 10-Q — filed 2026-05-15 — period 2026-03-31 — 10-Q
- Form 8-K — filed 2026-05-15 — period 2026-05-15 — FORM 8-K

---

Updated: 2026-10-23T06:09:42Z

Canonical page: https://altss.com/profile/traws-pharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology